Related Experiment Video
Updated: Jun 18, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review
Md Easin Mia1, Mithu Howlader1, Farzana Akter1
1Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Abstract:
The COVID-19 pandemic-led worldwide healthcare crisis necessitates prompt societal, ecological, and medical efforts to stop or reduce the rising number of fatalities. Numerous mRNA based vaccines and vaccines for viral vectors have been licensed for use in emergencies which showed 90% to 95% efficacy in preventing SARS-CoV-2 infection. However, safety issues, vaccine reluctance, and skepticism remain major concerns for making mass vaccination a successful approach to treat COVID-19. Hence, alternative therapeutics is needed for eradicating the global burden of COVID-19 from developed and low-resource countries. Repurposing current medications and drug candidates could be a more viable option for treating SARS-CoV-2 as these therapies have previously passed a number of significant checkpoints for drug development and patient care. Besides vaccines, this review focused on the potential usage of alternative therapeutic agents including antiviral, antiparasitic, and antibacterial drugs, protease inhibitors, neuraminidase inhibitors, and monoclonal antibodies that are currently undergoing preclinical and clinical investigations to assess their effectiveness and safety in the treatment of COVID-19. Among the repurposed drugs, remdesivir is considered as the most promising agent, while favipiravir, molnupiravir, paxlovid, and lopinavir/ritonavir exhibited improved therapeutic effects in terms of elimination of viruses. However, the outcomes of treatment with oseltamivir, umifenovir, disulfiram, teicoplanin, and ivermectin were not significant. It is noteworthy that combining multiple drugs as therapy showcases impressive effectiveness in managing individuals with COVID-19. Tocilizumab is presently employed for the treatment of patients who exhibit COVID-19-related pneumonia. Numerous antiviral drugs such as galidesivir, griffithsin, and thapsigargin are under clinical trials which could be promising for treating COVID-19 individuals with severe symptoms. Supportive treatment for patients of COVID-19 may involve the use of corticosteroids, convalescent plasma, stem cells, pooled antibodies, vitamins, and natural substances. This study provides an updated progress in SARS-CoV-2 medications and a crucial guide for inventing novel interventions against COVID-19.
Insights
Alternative therapeutics are crucial for combating COVID-19 due to vaccine concerns. This review explores repurposed drugs and novel agents, highlighting remdesivir and combination therapies as promising SARS-CoV-2 treatments.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- The COVID-19 pandemic necessitates urgent global healthcare interventions.
- Vaccines show high efficacy but face challenges like safety concerns and hesitancy.
- Alternative therapeutic strategies are vital for managing SARS-CoV-2 globally.
Purpose of the Study:
- To review alternative therapeutic agents for COVID-19 treatment beyond vaccines.
- To assess the effectiveness and safety of repurposed drugs and novel candidates.
- To provide an updated guide for developing new SARS-CoV-2 interventions.
Main Methods:
- Comprehensive review of preclinical and clinical investigations.
- Focus on antiviral, antiparasitic, antibacterial drugs, protease inhibitors, and monoclonal antibodies.
- Analysis of repurposed medications and supportive treatments.
Main Results:
- Remdesivir identified as a highly promising repurposed drug.
- Favipiravir, molnupiravir, paxlovid, and lopinavir/ritonavir show improved viral elimination.
- Combination therapy demonstrates significant effectiveness; tocilizumab used for pneumonia.
Conclusions:
- Repurposing existing drugs offers a viable therapeutic avenue for COVID-19.
- Several antiviral agents are under clinical trials for severe COVID-19 symptoms.
- Supportive treatments and novel interventions are crucial for comprehensive COVID-19 management.
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

